TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04403945

Intervention type: DEVICE
Intervention: Sidestream dark field(SDF) imagining
Description: SDF imaging consists of a hand-held device that illuminates a region by surrounding a central light guide with concentrically placed light emitting diodes,which thus provide SDF illumination.

Intervention type: DEVICE
Intervention: Sidestream dark field(SDF) imagining
Description: SDF imaging consists of a hand-held device that illuminates a region by surrounding a central light guide with concentrically placed light emitting diodes,which thus provide SDF illumination.

Intervention type: DEVICE
Intervention: Sidestream dark field(SDF) imagining
Description: SDF imaging consists of a hand-held device that illuminates a region by surrounding a central light guide with concentrically placed light emitting diodes,which thus provide SDF illumination.
Study: NCT01137734

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Adjustable Annuloplasty Ring with option to adjust off pump.
Description: Annuloplasty device repair of mitral valve regurgitation with option to adjust device post implant off pump, to optimize correction of mitral regurgitation. Unlike conventional annuloplasty repair, the Cardinal system offers the clinician the opportunity to make adjustments after weaning from cardiopulmonary bypass. Adjustability is expected to reduce the number of patients leaving the operating room with residual regurgitation after mitral valve repair.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Device: Adjustable Annuloplasty Ring (with option to adjust off-pump)
Description: Evaluate the performance and safety of the investigational adjustable annuloplasty ring device for the treatment of mitral regurgitation, with option to adjust on and off-pump.
Study: NCT03169621

Intervention type: PROCEDURE
Intervention: Endometrial Biopsy and endometrial fluid collection
Description: On day 5 of the Hormonal Replacement Therapy (after 5 days of progesterone administration), the doctor will perform endometrial fluid aspiration (EF) followed by an endometrial biopsy (EB) the same day of hysteroscopy that is performed as usual clinical practice. EF sample will be analyzed by molecular techniques (Next Generation Sequencing) for the detection of infectious agents and the EB sample will be divided into three parts, one of them will be used for molecular analysis (as control of the bacterial content present in the EF) and the others will be used for microbiological analysis and histological techniques respectively.~The Assisted Reproductive Treatment (ART) will be performed once the specialist considers it appropriated according to the clinical standard practice and the reproductive rates will be correlated with the diagnosis of CE comparing the results of ART before and after its diagnosis of CE.
Study: NCT03485027

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: the rechallenge regimen
Description: XELOX regimen: Oxaliplatin 130mg/m2, intravenous, on day 1; Capecitabine 1000mg/m2, oral, twice daily, continuously for 14 days; ±bevacizumab 7.5mg/kg, intravenous, on day 1; repeating every 3 weeks. FOLFOX regimen: Oxaliplatin 85mg/m2 on day 1; Calcium folinate 400mg/m2 on day 1; 5-FU 400mg/m2 on day 1; 5-FU 2.4g/m2, continuous intravenous infusion for 46 hours, ± Bevacizumab 5mg/kg or ± Cetuximab 500mg/m2, repeating every 2 weeks. FOLFIRI regimen: Irinotecan 180mg/m2 on day 1; Calcium folinate 400mg/m2 on day 1; 5-FU 400mg/m2 on day 1; 5-FU 2.4g/m2, continuous intravenous infusion for 46 hours; ± Bevacizumab 5mg/kg or ± Cetuximab 500mg/m2, repeating every 2 weeks. Irinotecan monotherapy regimen: Irinotecan 180mg/m2 on day 1, ± Bevacizumab 5mg/kg or ± Cetuximab 500mg/m2, repeating every 2 weeks. Raltitrexed contained regimen: Raltitrexed 3mg/m2 on day 1; ± Bevacizumab 7.5mg/kg, repeating every 3 weeks; Raltitrexed 2mg/m2 on day 1; ± Cetuximab 500mg/m2, repeating every 2 weeks.
Study: NCT01402934

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hydroxyethyl starch solution (Voluven) infusion
Description: fluid loading will be performed by hydroxyethyl starch solution (Voluven), at 6 mL/kg
Study: NCT03614455

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Milademetan
Description: Milademetan 100 mg capsule for oral administration

Intervention type: DRUG
Group type: OTHER
Intervention: Milademetan
Description: Milademetan 100 mg capsule for oral administration

Intervention type: DRUG
Group type: OTHER
Intervention: Milademetan
Description: Milademetan 100 mg capsule for oral administration

Intervention type: DRUG
Group type: OTHER
Intervention: Itraconazole
Description: Itraconazole (200 mg) oral solution (20 mL of 10 mg/mL)

Intervention type: DRUG
Group type: OTHER
Intervention: Posaconazole
Description: Posaconazole (200 mg) oral suspension (5 mL of 40 mg/mL)
Study: NCT03171064

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resistance and Endurance Exercise
Description: Machine-based, 2x/week endurance and resistance training for 12 weeks
Study: NCT02219009

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MIND1 System
Description: Subjects will receive aripiprazole tablets embedded with an IEM. They will discontinue their normally prescribed oral aripiprazole tablets and will take the aripiprazole + IEM tablets (eg, at the previously prescribed dose) during the 8-week treatment period for this study. Aripiprazole + IEM tablets must be taken on a once-daily dosing schedule.
Study: NCT01510509

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Titanium bare metal stent (Titan2®)
Description: Titan2®, Hexacath, Paris, France

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Everolimus Drug Eluting Stent (Xience-V®)
Description: Xience-V®, Abbott Vascular, Santa Clara, California, USA
Study: NCT03988543

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient Self-management
Description: Enhanced care (EC) approach aimed to engage participants actively, and to increase self-efficacy, in the monitoring and managing of their symptoms. After patients complete the current EHR-integrated symptom monitoring, they will receive web-based, patient-centered information to gain knowledge on cancer-related outcomes, improve self-management skills, improve communication skills, and empower them to improve motivation and self-management.
Study: NCT01920009

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Pharmacist counselling session with a motivational interview
Description: The intervention:~The patient will be invited by the community pharmacist for two consultations the first 2 weeks after discharge and the second after 3 months.~The intervention group consultation:~Community pharmacy consultation around 2 weeks The consultation will take place in the pharmacy a face to face consultation for 20 minutes including; Motivational interview session, the pharmacists will incorporate the key motivational interview skills in their consultation Express empathy, develop discrepancy, role with resistance, support self efficacy.~The sessions will aim to develop a partnership between the pharmacist with the patient and exchange information to facilitate an informed decision. Furthermore both the pharmacist and the patient will negotiate behaviour and reach an agreement. The goal is to access motivation and elicit commitment to change behaviour in this case would be adherence to life saving medication
Study: NCT02710734

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinblastine
Description: Administered Day 1 of each 14 day cycle for 3 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Administered Day 1 of each 14 day cycle for 3 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Administered Day 1 of each 14 day cycle for 3 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Administered Day 1 of each 14 day cycle for 3 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Administered Day 1 of each 14 day cycle for 3 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Administered Day 1 of each 14 day cycle for 3 cycles
Study: NCT04338984

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: General anesthetic
Description: Fentanyl is administered at induction - standard dose 5 mcg/kg. Further dosing is based on a multiderivative assessment of nociception (NOL index) and ancillaries such as heart rate and mean arterial blood pressure.
Study: NCT03289455

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AUTO3 (CD19/22 CAR T cells
Description: Following preconditioning with chemotherapy (cyclophosphamide and fludarabine) patients will be treated with 1 to 5.0 x 10⁶/kg CD19/CD22 Chimeric Antigen Receptor (CAR) positive T cells as a single or split dose.
Study: NCT03888911

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High dose IQP-LU-104 (5120mg)
Description: 1 sachet to be taken 2 times daily orally, together with 2 main meals

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Low dose IQP-LU-104 (2560mg)
Description: 1 sachet to be taken 2 times daily orally, together with 2 main meals

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 sachet to be taken 2 times daily orally, together with 2 main meals
Study: NCT02919085

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Early ambulation
Description: Procedure to accelerate the ability of a patient to walk or move about by reducing the time to ambulation. It is characterized by a shorter period of hospitalization or recumbency than is normally practiced.
Study: NCT02138513

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Based Cognitive Therapy
Description: This MBCT protocol consists of 8 weekly sessions of 2,5 hours each and a silent day of 6 hours of meditation practice. Similar to group MBCT, in the online MBCT group, participants will be asked to practice at home for 45 minutes, 6 days a week. They will receive files with meditation and yoga exercises to support this.
Study: NCT04338984

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.5% Injectable Solution
Description: Bilateral single shot erector spinae plane block is performed before induction of general anaesthesia.~Ropivacaine 0.5% total dose 3mg/kg with Dexamethasone 8mg/20 ml Ropivacaine 0.5%.
Study: NCT00488280

Intervention type: BEHAVIORAL
Intervention: Locomotor Training
Description: Task-specific practice of walking with assistance from trainers using body weight support and treadmill followed by training over ground, 5x/week, approximately 1.5 hours/day
Study: NCT03370614

Intervention type: OTHER
Intervention: IBS Group
Description: Participants will receive approximately 2 months of dietary and nutritional counseling.

Intervention type: OTHER
Intervention: Healthy Control Group
Description: Participants will not receive any dietary or nutritional counseling.
Study: NCT04216160

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ACN cream (YUN)
Description: Application of the facial cream ACN (YUN) twice a day, for 8 weeks +/- 2 days. Assessment before product use (T0), after 2, 4 and 8 weeks +/- 2 days of product use (T2w, T4w and T8w, respectively) and after 4 weeks +/- 2 days without product use (T12w).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo cream (YUN)
Description: Application of the facial placebo cream twice a day, for 8 weeks +/- 2 days. Assessment before product use (T0), after 2, 4 and 8 weeks +/- 2 days of product use (T2w, T4w and T8w, respectively) and after 4 weeks +/- 2 days without product use (T12w).
Study: NCT02185664

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: landmark technique
Description: The apex of the imaginary triangle formed between the two heads of sternocleidomastoid and clavicle was used as the point of needle entry, just lateral to the pulsation of the internal carotid artery and directed towards the ipsilateral nipple at an angle of 45 degrees.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Static Ultrasound technique
Description: Static ultrasound guided internal jugular vein cannulation was performed by using the transthoracic echocardiography probe supplied with the transesophageal echocardiography machine in the cardiothoracic surgery operation theatre. The internal jugular vein was located and marked using this method prior to puncture.
Study: NCT03710876

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: rAd-IFN
Description: Adenovirus-Delivered Interferon Alpha-2b
Study: NCT02710734

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Administered Day 1 of each 14 day cycle for 3 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Administered Day 1 of each 14 day cycle for 3 cycles
Study: NCT03710876

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Celecoxib Oral Product
Description: 400 mg twice daily
Study: NCT03196479

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ketamine and propofol mixture with 1:6 ratio
Description: K16: K16 group was received ketamine:propofol with ratio of 1:6, filled in 50 cc syringe, which consisted of 1 ml of ketamine (50 mg/ml), 30 ml of 1% propofol (10 mg/ml), and 19 ml of normal saline so that every ml of mixture consisted of 1 mg of ketamine and 6 mg of propofol
Study: NCT02429609

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Moorfields Acuity Chart
Study: NCT03710876

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Celecoxib Oral Product
Description: 400 mg twice daily
Study: NCT04252820

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: WarmTouch total body blanket, Covidien Ltd, Mansfield, USA
Description: Forced-air warming will be applied in the preanesthetic room

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: WarmTouch total body blanket, Covidien Ltd, Mansfield, USA
Description: Forced-air warming will be applied in the preanesthetic room

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: WarmTouch total body blanket, Covidien Ltd, Mansfield, USA
Description: Forced-air warming will be applied in the preanesthetic room
Study: NCT00601965

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Escitalopram
Description: 20 mg daily oral escitalopram

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Escitalopram
Description: 20 mg daily oral escitalopram

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo pill of daily oral escitalopram

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo pill of daily oral escitalopram

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy (CBT)
Description: 16 weekly 1-hour sessions

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Cognitive behavioral therapy (CBT)
Description: 16 weekly 1-hour sessions
Study: NCT02042443

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin Calcium
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib
Description: Given PO
Study: NCT02882503

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: endoscopic ultrasound - radiofrequency ablation (EUS-RFA)
Description: Radiofrequency ablation will be applied with an innovative monopolar radiofrequency probe (1.2 mm Habib EUS-RFA catheter) placed through a 19 or 22 gauge fine needle aspiration (FNA) needle in patients with a tumor in the head of the pancreas.
Study: NCT03341026

Intervention type: OTHER
Group type: OTHER
Intervention: Metronom CGM device
Description: Patient receives three Metronom CGM devices on day 1. On day 1, 4, 7 and 14, a hypo- or hyperglycaemic experiment will start according to allocation by randomizer.

Intervention type: OTHER
Group type: OTHER
Intervention: Metronom CGM device
Description: Patient receives three Metronom CGM devices on day 1. On day 1, 7, 10 and 14, a hypo- or hyperglycaemic experiment will start according to allocation by randomizer.
Study: NCT03000712

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous Adipose Tissue derived MSCs 1x10^8cells/3ml
Description: biological : Autologous Adipose Tissue derived MSCs 1x10\^8cells/3ml drug: saline solution
Study: NCT00740272

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: AF ablation + pacemaker implantation
Description: regular pacemaker implantation and concomitant AF ablation procedure (PV isolation)
Study: NCT03710876

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Gemcitabine
Description: 1250 mg/m2 administered intravenously on Days 1 and 8 of a 21-day cycle and continued every 3 weeks until disease progression/ early termination
Study: NCT02710734

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Administered Day 1 of each 14 day cycle for 3 cycles
Study: NCT00740272

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pacemaker implantation
Description: regular pacemaker implantation
Study: NCT03957980

Intervention type: OTHER
Group type: OTHER
Intervention: Occupational therapy
Description: Child/caregiver dyads in this group will participate in telehealth-based intervention sessions in their home environment. Each child/caregiver dyad will participate in up to 9 interventions sessions. All intervention sessions will last 30-60 minutes. The intervention sessions will focus on task analysis, caregiver coaching, parent education and recommendations for task and home/environmental modifications to promote the child's functional vision.

Intervention type: OTHER
Group type: OTHER
Intervention: Occupational therapy
Description: Child/caregiver dyads in this group will participate in telehealth-based intervention sessions in their home environment. Each child/caregiver dyad will participate in up to 9 interventions sessions. All intervention sessions will last 30-60 minutes. The intervention sessions will focus on task analysis, caregiver coaching, parent education and recommendations for task and home/environmental modifications to promote the child's functional vision.
Study: NCT00555581

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imatinib Mesylate
Description: In initial phase, patients will be treated with Gleevec 400 mg daily for 12 months. In the extension phase, patients will be treated with Gleevec 400 mg daily for 27 months.
Study: NCT03057561

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cardiac MRI taken using contrast agent, Dotarem® (Gd-DOTA)
Description: Gadolinium based contrast agent used in cardiac MRI scanning using 3.0 Tesla MRI

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cardiac MRI taken using contrast agent, Dotarem® (Gd-DOTA)
Description: Gadolinium based contrast agent used in cardiac MRI scanning using 3.0 Tesla MRI

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cardiac MRI with contrast agent, Gadovist
Description: Brand of Gd-DO3A-butrol; contrast agent used in cardiac MRI scanning using 3.0 Tesla MRI

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cardiac MRI with contrast agent, Gadovist
Description: Brand of Gd-DO3A-butrol; contrast agent used in cardiac MRI scanning using 3.0 Tesla MRI
Study: NCT03929731

Intervention type: DIAGNOSTIC_TEST
Intervention: Indocyanine Green Angiography
Description: Intravenous injection of dye-indocyanine green
Study: NCT04083183

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Astatine At 211 Anti-CD45 Monoclonal Antibody BC8-B10
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Lapine T-Lymphocyte Immune Globulin
Description: Given IV

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total-Body Irradiation
Description: Undergo TBI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hematopoietic Cell Transplantation
Description: Undergo hematopoietic cell transplantation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil
Description: Given PO or IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: Given PO

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Aspiration
Description: Undergo bone marrow aspiration

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection
Study: NCT01197885

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMAB362
Description: Cohort 1 repeated doses of 300 mg/m2 Cohort 2 repeated doses of 600 mg/m2 Cohort 3 doses to be determined, 600mg/m2 or less
Study: NCT03710876

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: 1250 mg/m2 administered intravenously on Days 1 and 8 of a 21-day cycle and continued every 3 weeks until disease progression/ early termination
Study: NCT02710734

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity modulated radiation therapy (IMRT)
Description: 2.0 Gy per fraction to the whole bladder plus a margin for a total of 32 fractions (64.0 Gy). Radiation will be administered from Monday to Friday

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transurethral Resection of Bladder tumor
Description: Performed at before and after AMVAC and after chemoradiation and intravesicle therapy
Study: NCT03409068

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: C2-C4 compartment anesthetic block
Description: C2-C4 compartment anesthetic block is performed by injecting levobupivacaine 0.375% 20 mL between the posterior face of the middle scalenus muscle, the anterior face of the posterior scalene muscle and the lower plane of the sternoscleidomastoid muscle.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Costagliola block
Description: Costagliola block is performed by injected by injecting levobupivacaine 0.375% 20 mL along the anterior and the posterior border of sternocleidomastoid muscle
Study: NCT00181623

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant Human Prolactin